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Abstract 
Introduction: An active area of tobacco regulatory science research focuses on 
examining the effects of varying the nicotine content of cigarettes as part of a potential 
national policy to lower their nicotine content levels to reduce addiction potential. The 
present study examines differences in the behavioral effects of reduced nicotine content 
cigarettes related to their menthol status.  Menthol is the only cigarette flavoring that is 
still legally permissible according to Food and Drug administration regulations.  
Methods: Participants were 26 current adult smokers from three populations especially 
vulnerable to tobacco use and addiction (economically disadvantaged women, opioid-
dependent individuals, individuals with affective disorders) dichotomized as menthol 
(n=11) or non-menthol (n=15) smokers. Participants completed 14 experimental sessions 
following acute smoking abstinence (CO<50% baseline level). Across sessions, 
participants smoked four Spectrum research cigarettes (22nd Century Group, Clarence, 
NY) with varying nicotine content levels (0.4mg/g, 2.4 mg/g, 5.2 mg/g, 15.8 mg/g) or 
their usual brand cigarette.  Research cigarettes were mentholated or non-mentholated 
corresponding to participants usual brand.  Upon completion of smoking, participants 
completed tasks measuring reinforcing efficacy, subjective effects, topography, and 
withdrawal and craving measures.  Repeated Measures Analysis of Variance was used for 
all analyses (p<.05). 
Results: Main effects of menthol status, as well as interactions of nicotine dose and 
menthol were noted across subscales of subjective effects and direct assessments of 
reinforcing efficacy. Usual brand mentholated cigarettes produced a profile of equal or 
greater relative reinforcing effects than usual brand non-mentholated cigarettes, while 
mentholated research cigarettes produced a profile of effects that fell below (i.e., lower 
relative reinforcing effects compared to usual brand or non-mentholated cigarettes) those 
of non-mentholated research cigarettes.  
Conclusions: Mentholated research cigarettes produce a lower profile of reinforcing and 
subjective effects, without discernible differences in smoking topography. The potential 
impact of mentholation on reinforcing efficacy and subjective effects should be 
considered when using Spectrum research cigarettes. 
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Comprehensive Literature Review 
 
Despite a steady decline in smoking prevalence since the landmark U.S. 
Surgeon’s General report in 1964 highlighting the deleterious health consequences of 
smoking, cigarette smoking remains a serious U.S. public health problem.  Smoking is 
responsible for an estimated 480,000 premature deaths and $300 billion dollars annually 
in both health and lost productivity costs (U.S. Department of Health and Human 
Services, 2014). To address this public health challenge, the Family Smoking Prevention 
and Tobacco Control Act was passed in 2009 giving the Food and Drug Administration 
(FDA) regulatory authority over the manufacturing and marketing of cigarettes and other 
tobacco products. This Act gives the FDA authority to reduce, although not eliminate, the 
amount of nicotine in cigarettes if deemed in the interest of protecting public health.  
NICOTINE REDUCTION 
There is overwhelming evidence that nicotine is the constituent in tobacco smoke 
that promotes chronic smoking and nicotine dependence (U.S  Department of Health and 
Human Services, 1988, 2012, 2014). Currently, the FDA is supporting research 
investigating, among other things, the impact of reducing nicotine content levels in 
cigarettes below a hypothesized addiction threshold (Benowitz & Henningfield, 1994). 
Research supported by these initiatives has suggested that acute exposure to cigarettes 
with reduced nicotine content decreases the reinforcing effects and other subjective 
effects of smoking at these lowered doses compared to cigarettes with higher nicotine 
contents without evidence of promoting compensatory smoking (Higgins et al., 2017). 
Investigations of extended exposure to cigarettes with reduced nicotine content levels 
	 2	
illustrate a decrease in cigarettes smoked per day (CPD) and nicotine dependence severity 
relative to cigarettes with a nicotine content level similar to what is in commercial 
cigarettes (e.g., Donny et al., 2015). This research is being used to help the FDA examine 
the feasibility and potential efficacy of a national policy that reduces the maximal 
nicotine content of cigarettes to very low levels. Importantly, as smoking rates continue 
to decline, certain populations, who may be especially vulnerable to smoking, show 
increases in smoking, higher dependence levels, and lower cessation rates (Higgins et 
al. 2016; Higgins & Chilcoat 2009; Hiscock et al. 2012). 
MENTHOLATION IN CIGARETTES 
Other constituents of cigarette tobacco that may have an impact on smoking 
prevalence and dependence risk are being considered by the FDA as well. One 
constituent that affects a large proportion of current cigarette smokers is cigarette 
flavoring (i.e., mentholation). In addition to giving the FDA authority to set nicotine 
standards, the 2009 Family Smoking Prevention and Tobacco Control Act grants FDA 
authority over flavorings in cigarettes including menthol (Family Smoking Prevention 
and Tobacco Control Act, 2009). Currently all flavorings in cigarettes other than menthol 
are banned. Approximately one-third of the U.S. cigarette market is made up of menthol-
flavored cigarettes (Federal Trade Commission Report, 2013). Menthol cigarettes are 
distinct from non-menthol cigarettes due to their unique sensory effects, such as the 
reported ‘cooling’ that menthol provides. Individuals who smoke menthol cigarettes tend 
to do so exclusively and generally express preference for the sensory experience provided 
by the menthol cigarette (Kreslake, Wayne, Connolly 2008). As the only flavoring legally 
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allowable in cigarettes, it is important to consider the impact mentholation could 
potentially have on the acceptability of reduced nicotine content cigarettes.  
In the way of background, menthol is a chemical compound derived from the oil 
of the peppermint and corn mint plants or can be created synthetically to provide a 
distinct mint-like flavor (Tobacco Product and Scientific Advisory Committee (TPSAC) 
Report, 2011). Menthol was first added to cigarettes in the mid 1920s, yet did not reach 
mainstream popularity until the mid 1930s (Tobacco Product and Scientific Advisory 
Committee (TPSAC) Report, 2011). Menthol flavoring is added to cigarettes in a variety 
of ways, most commonly by spraying an alcohol based menthol solution on the tobacco 
during blending or applying menthol product to the filter during cigarette filter 
manufacturing. Other technologies to add menthol to cigarettes include spraying an 
alcohol based menthol solution onto the inner foil of the packaging, inserting crushable 
mentholated beads in the filter, mentholated threads, or mentholated crushable 
microbeads that fill a filler cavity or are mixed into the filter (R.J. Reynolds, Altria Client 
Services, 2010). Although cigarettes marketed as non-menthol often have some level of 
menthol (< 0.1 mg/cigarette) in the product (Ai et al., 2016), detectable levels of menthol 
in cigarettes are approximately 0.6 – 1.5 mg/cigarette (Heck et al., 2010). Recent analyses 
of 23 non-menthol and menthol cigarette brands determined that menthol content in 
cigarettes advertised as menthol range widely from 2.9 – 19.6 mg/cigarette and menthol 
content in non-menthol cigarettes ranges from 0.0002 to 0.07mg/cigarette (Ai et al., 
2016).  
An estimated 39% of U.S. current smokers report regular use of mentholated 
cigarettes (Villanti et al., 2016). This represents an increase from 35% in 2008-2010 
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(Villanti et al., 2016), suggesting that while overall smoking prevalence continues to 
decline, menthol cigarette use does not follow that pattern. Smokers of menthol cigarettes 
tend to be younger, non-white, and female relative to non-menthol smokers (Giovino et 
al., 2015; Lawrence et al., 2010; SAMSHA, 2011; Villanti et al., 2016). There are mixed 
findings on dependence and smoking cessation among menthol smokers (see Hoffman & 
Simmons, 2011a and Frost-Pineda, Muhammad-Kah, Rimmer, & Liang, 2014 for 
reviews) with some literature suggesting greater nicotine dependence and lower cessation 
rates in menthol smokers (Ahijevych & Garrett, 2010; Fagan et al., 2015) and others 
suggesting no differences (Hoffman & Sommons, 2011b; Hyland, Garten, Giovino, & 
Cummings, 2002). 
There is a literature examining the role that mentholation has on the sensory 
experience of smoking and how associated responses to smoking, such as craving, 
withdrawal, and subjective experience are affected. This literature suggests that 
mentholation acts as a cue or discriminative stimulus for menthol smokers and that 
removal or altering of that stimulus can affect the smoking experience (Rose & Behm, 
2004). A recent study comparing withdrawal and craving reduction among menthol and 
non-menthol smokers illustrates this point. When intravenous (IV) nicotine was 
administered under acute abstinence to both the menthol and non-menthol smoker 
groups, menthol smokers reported significantly less reduction of smoking urges 
compared to non-menthol smokers and a trend towards less reduction of withdrawal 
symptoms (Devito et al., 2016). Those differences remained after controlling for potential 
confounding of race and gender. This blunted response to the IV nicotine in the menthol 
relative to non-menthol group suggests that menthol may provide a distinct stimulus 
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profile that at least in part may mediate other effects of smoking such as changes in 
craving and withdrawal as outlined above. Considered together, the literature on 
mentholation suggests that its potential influence on the smoking experience should be 
considered in any research involving menthol smokers.  
MENTHOL CONTENT AND NICOTINE REDUCTION 
To my knowledge, only two studies have been reported addressing the question of 
how smokers of non-menthol versus menthol reduced nicotine content cigarettes may 
differ. Pickworth and colleagues (2002) administered three cigarettes with varying 
nicotine yield in a double-blind, within-session study; a commercial cigarette with a yield 
typical of commercial cigarettes (1.1 mg), a high nicotine yield research cigarette (2.5 
mg), and a low nicotine yield research cigarette (0.2 mg). It should be noted that in this 
study nicotine yield is used as an indicator of potential nicotine exposure level as opposed 
to nicotine content. Nicotine yield is machine-measured exposure to nicotine when a 
cigarette is smoked in a standardized way (Federal Trade Commission Report, 2000). 
Often smokers will engage in compensatory smoking (e.g., increasing puff volume) to 
obtain a greater nicotine yield than the machine-estimated value (see Scherer and Lee 
2014 for a review). Thirty-six participants were assigned their preferred mentholation (i.e 
menthol or non-menthol) and directed to smoke all three cigarettes over a single 
laboratory session. Half of the subjects were regular menthol smokers and half non-
menthol smokers. Ratings of subjective experience were assessed using the Cigarette 
Evaluation Questionnaire (CEQ) (Westman et al., 1992) and the Duke Sensory 
Questionnaire (Rose & Behm, 2004). Both questionnaires were developed to understand 
the sensory and positive subjective effects of smoking. Number of puffs taken for each 
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cigarette and time to smoke each cigarette was examined as a proxy for compensatory 
smoking. Physiological measures of heart rate, blood pressure, and changes in carbon 
monoxide (CO) were collected as well. No differences by menthol status were reported 
for physiological measures and the commercial and high-yield cigarettes produced 
greater changes in physiological outcomes than the low-yield cigarette overall. There was 
a significant effect of mentholation on subjective effects, although it was restricted to 
only the high dose. At the highest nicotine yield cigarette, menthol smokers reported the 
cigarette to be less satisfying and provided less relief from craving compared to non-
menthol smokers (Pickworth et al., 2002).  
The second study (Hatsukami et al., 2013) was an initial examination of Spectrum 
research cigarettes (22nd Century Group), which are currently used exclusively by the 
FDA for purposes of examining nicotine content and are the type that is used in the 
present study as well. The nicotine content levels in Spectrum cigarettes are altered by 
genetically modifying the tobacco. Fifty-one participants smoked four puffs of three 
research cigarettes with different nicotine doses (nicotine content 0.4 mg/g, 5.7-5.8 mg/g, 
11.4-12.8 mg/g; nicotine yields >.04 mg, 0.3 mg, 0.6 mg, respectively) over the course of 
a single session in double-blind, random order. Participants were assigned menthol or 
non-menthol cigarettes based on their usual brand preference, with approximately half of 
participants (47%) being menthol cigarette smokers. After smoking each cigarette, 
participants were given a modified version of the CEQ used by Pickworth and colleagues 
where subjective effects of smoking are rated on five subscales (Satisfaction, 
Psychological Reward, Enjoyment of Respiratory Tract Sensations, Aversion, and 
Craving Reduction).  They also assessed a scale of Perceived Health Risk in which 
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participants rated the perceived disease risk of these products as well as the Multiple 
Choice Procedure (MCP, Griffiths, Troisi, Silverman, & Mumford, 1993), which assesses 
relative reinforcing effects by having participants indicate at what monetary value they 
would forego a pack of cigarettes for money. Physiological measures of heart rate and 
blood pressure were collected as well. 
Overall, reducing nicotine content produced orderly, dose-dependent decreases 
across the battery of dependent measures. There were also significant differences in how 
the menthol and non-menthol smokers rated the cigarettes. Across doses, menthol 
smokers rated the research cigarettes as less satisfying, psychologically rewarding, and 
pleasing to the respiratory tract compared to non-menthol smokers. Menthol smokers also 
reported smaller craving reductions than non-menthol smokers. A similar finding was 
seen with relative reinforcing effects in the MCP, with menthol smokers choosing to 
switch to money at a lower monetary value indicating less reinforcing effects compared 
to non-menthol smokers. No interaction between menthol status and nicotine dose was 
reported suggesting that ratings were shifted downward among menthol compared to 
non-menthol smokers across the varying dose cigarettes. That differs from the results in 
Pickworth et al. (2002) where differences by menthol status were discerned only at the 
high nicotine yield cigarette.  
Considered together, these two studies suggest that when nicotine exposure levels 
are altered, effects may differ by menthol status of the smoker, although there is some 
discrepancy over where in the dose-effect curve such discrepancies are discerned. 
Additionally, these two studies leave some gaps where further research is needed. The 
first is the use of a comparison of usual brand relative to research cigarette ratings. In the 
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Pickworth et al. (2002) study, participants smoked mentholated or non-mentholated 
commercial cigarettes that corresponded with whether their usual brand was mentholated 
or non-mentholated, but the cigarettes were not necessarily the participant’s usual brand. 
Previous research suggests that when menthol users are switched to another menthol 
cigarette of similar nicotine content, subjective ratings can be lower (Strasser et al., 
2013). Therefore, it is important to use the participants’ usual brand, instead of a proxy, 
as a true baseline. In the Hatsukami et al. (2013) study, participants first smoke their 
usual brand cigarette, but usual brand cigarette findings were not included in the 
analyses. Having a usual-brand comparison could be useful to see how smoking 
experience of the research cigarettes compares with the participant’s typical smoking 
experience. Finally, findings from the prior studies could be extended by examining 
effects across additional outcome measures. For example, examining them across well-
validated measures of smoking topography, craving and withdrawal, and additional 
measures of relative reinforcing effects including concurrent choice (Higgins et al., 1994) 
and the behavioral-economic Cigarette Purchase Task (Jacobs & Bickel, 1999) could help 
to elucidate the range and type of outcomes on which menthol and non-menthol users 
vary in response to reduced nicotine cigarettes.  
CURRENT STUDY 
As discussed above, the overarching goal of FDA-supported research into reduced 
nicotine content cigarettes is to determine how individuals may respond to a policy of 
reduced nicotine standards. The findings from this program of research could have 
substantial impact on current smokers. If menthol and non-menthol smokers respond 
differently to reduced nicotine content cigarettes, it is important to determine as 
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thoroughly as possible the nature and breadth of these differences. The aim of the current 
investigation is to use a rigorous, within-subject research design to examine differences 
by menthol status across a wide range of nicotine doses (0.4mg/g, 2.4mg/g, 5.2mg/g, 
15.8mg/g of Spectrum research cigarettes) as well as by usual-brand cigarettes across a 
relatively comprehensive battery of outcomes assessing the behavioral pharmacology of 
smoking.  
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Abstract 
Introduction: An active area of tobacco regulatory science research focuses on 
examining the effects of varying the nicotine content of cigarettes as part of a potential 
national policy to lower their nicotine content levels to reduce addiction potential. The 
present study examines differences in the behavioral effects of reduced nicotine content 
cigarettes related to their menthol status.  Menthol is the only cigarette flavoring that is 
still legally permissible according to Food and Drug administration regulations.  
Methods: Participants were 26 current adult smokers from three populations especially 
vulnerable to tobacco use and addiction (economically disadvantaged women, opioid-
dependent individuals, individuals with affective disorders) dichotomized as menthol 
(n=11) or non-menthol (n=15) smokers. Participants completed 14 experimental sessions 
following acute smoking abstinence (CO<50% baseline level). Across sessions, 
participants smoked four Spectrum research cigarettes (22nd Century Group, Clarence, 
NY) with varying nicotine content levels (0.4mg/g, 2.4 mg/g, 5.2 mg/g, 15.8 mg/g) or 
their usual brand cigarette.  Research cigarettes were mentholated or non-mentholated 
corresponding to participants usual brand.  Upon completion of smoking, participants 
completed tasks measuring reinforcing efficacy, subjective effects, topography, and 
withdrawal and craving measures.  Repeated Measures Analysis of Variance was used for 
all analyses (p<.05). 
Results: Main effects of menthol status, as well as interactions of nicotine dose and 
menthol were noted across subscales of subjective effects and direct assessments of 
reinforcing efficacy. Usual brand mentholated cigarettes produced a profile of equal or 
greater relative reinforcing effects than usual brand non-mentholated cigarettes, while 
mentholated research cigarettes produced a profile of effects that fell below (i.e., lower 
relative reinforcing effects compared to usual brand or non-mentholated cigarettes) those 
of non-mentholated research cigarettes.  
Conclusions: Mentholated research cigarettes produce a lower profile of reinforcing and 
subjective effects, without discernible differences in smoking topography. The potential 
impact of mentholation on reinforcing efficacy and subjective effects should be 
considered when using Spectrum research cigarettes. 
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Introduction 
Despite a steady decline of smoking prevalence since the landmark U.S. 
Surgeon’s General report in 1964 highlighting the deleterious health consequences of 
smoking, cigarette smoking remains a serious U.S. public health problem. Smoking is 
responsible for 480,000 deaths and $300 billion dollars annually in both health and lost 
productivity costs (U.S. Department of Health and Human Services, 2014). To address 
this public health challenge, the Family Smoking Prevention and Tobacco Control Act 
was passed in 2009 giving the Food and Drug Administration (FDA) regulatory authority 
over the manufacturing and marketing of cigarettes and other tobacco products. This Act 
gives the FDA authority to reduce, although not eliminate, the amount of nicotine in 
cigarettes if deemed in the interest of protecting public health.  
There is overwhelming evidence that nicotine is the constituent in tobacco smoke 
that promotes chronic smoking and nicotine dependence (U.S  Department of Health and 
Human Services, 1988, 2012, 2014). Currently, the FDA is supporting research 
investigating, among other things, the impact of reducing nicotine content levels in 
cigarettes below a hypothesized addiction threshold (Benowitz & Henningfield, 1994). 
Research supported by these initiatives has suggested that acute exposure to cigarettes 
with reduced nicotine content decreases the reinforcing effects and other subjective 
effects of smoking at these lowered doses compared to cigarettes with higher nicotine 
contents without evidence of promoting compensatory smoking (Higgins et al., 2017). 
Investigations of extended exposure to cigarettes with reduced nicotine content levels 
illustrate a decrease in cigarettes smoked per day (CPD) and nicotine dependence severity 
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relative to cigarettes with a nicotine content level similar to what is in commercial 
cigarettes (e.g., Donny et al., 2015). This research is being used to help the FDA examine 
the feasibility and potential efficacy of a national policy that reduces the maximal 
nicotine content of cigarettes to very low levels. Importantly, as smoking rates continue 
to decline, certain populations, who may be especially vulnerable to smoking, show 
increases in smoking, higher dependence levels, and lower cessation rates (Higgins et 
al. 2016; Higgins & Chilcoat 2009; Hiscock et al. 2012).  
Other constituents of cigarette tobacco that may have an impact on smoking 
prevalence and dependence risk are being considered by the FDA as well. One 
constituent that affects a large proportion of current cigarette smokers is cigarette 
flavoring (i.e., mentholation). In addition to giving the FDA authority to set nicotine 
standards, the 2009 Family Smoking Prevention and Tobacco Control Act grants FDA 
authority over flavorings in cigarettes including menthol (Family Smoking Prevention 
and Tobacco Control Act, 2009). Currently all flavorings in cigarettes other than menthol 
are banned. Approximately one-third of the cigarette market is made up of menthol-
flavored cigarettes (Federal Trade Commission Report, 2013). Menthol cigarettes are 
distinct from non-menthol cigarettes due to their unique sensory effects, such as the 
reported ‘cooling’ that menthol provides. Individuals who smoke menthol cigarettes tend 
to do so exclusively and generally express preference for the sensory experience provided 
by the menthol cigarette (Kreslake, Wayne, Connolly 2008). As the only flavoring legally 
allowable in cigarettes, it is important to consider the impact mentholation could 
potentially have on the acceptability of reduced nicotine content cigarettes.  
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In the way of background, menthol is a chemical compound derived from the oil 
of the peppermint plant and corn mint plants or can be created synthetically to provide a 
distinct mint-like flavor (Tobacco Product and Scientific Advisory Committee (TPSAC) 
Report, 2011). Although cigarettes marketed as non-menthol often have some level of 
menthol (< 0.1 mg/cigarette) in the product (Ai et al., 2016), detectable levels of menthol 
in cigarettes are approximately 0.6 – 1.5 mg/cigarette (Heck et al., 2010) and recent 
analyses of 23 non-menthol and menthol cigarette brands determined that menthol 
content in cigarettes advertised as menthol ranges widely from 2.9 – 19.6 mg/cigarette 
and menthol content in non-menthol cigarettes ranges from 0.0002 to 0.07mg/cigarette 
(Ai et al., 2016).  
An estimated 39% of U.S. current smokers report regular use of mentholated 
cigarettes (Villanti et al., 2016). This represents an increase from 35% in 2008-2010 
(Villanti et al., 2016), suggesting that while overall rates of smoking continue to decline, 
menthol cigarette use does not follow that pattern. Smokers of menthol cigarettes tend to 
be younger, non-white, and female relative to non-menthol smokers (Giovino et al., 2015; 
Lawrence et al., 2010; SAMSHA, 2011; Villanti et al., 2016).  
There is an existing literature examining the role that mentholation has on the 
sensory experience of smoking and how associated responses to smoking, such as 
craving, withdrawal, and subjective experience are affected. The literature suggests that 
mentholation acts as a cue or discriminative stimulus for menthol smokers and that 
removal or altering of that stimulus can affect the smoking experience (Rose & Behm, 
2004; Devito et al., 2016). This literature on menthol cigarettes suggests that the potential  
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influence of mentholation on the smoking experience should be considered in research in 
menthol smokers.  
To our knowledge, only two studies relevant to this question have been reported. 
The earlier study was an examination of the sensory and physiological effects of 
cigarettes that varied in nicotine yield. Pickworth and colleagues (2002) administered 
three cigarettes with varying nicotine yield in a double-blind, within-session study; a 
commercial cigarette with a yield typical of commercial cigarettes (1.1 mg), a high 
nicotine yield research cigarette (2.5 mg), and a low nicotine yield research cigarette (0.2 
mg). Thirty-six participants were assigned their preferred mentholation (i.e menthol or 
non-menthol) and directed to smoke all three cigarettes over a single laboratory session. 
Half of the subjects were menthol smokers and half non-menthol smokers. Ratings of 
subjective experience, measured by the Cigarette Evaluation Questionnaire (CEQ) 
(Westman et al., 1992) and the Duke Sensory Questionnaire (Rose & Behm, 2004), were 
examined. Both questionnaires were developed to understand the sensory and positive 
subjective effects of smoking. Number of puffs taken for each cigarette and time to 
smoke each cigarette was examined as a proxy for compensatory smoking. Physiological 
measures of heart rate, blood pressure, and changes in carbon monoxide (CO) were 
collected as well. No differences by menthol status were reported for physiological 
measures and the commercial and high-yield cigarettes produced greater changes in 
physiological outcomes than the low-yield cigarette overall. There was a significant 
effect of mentholation on subjective effects, although it was restricted to only the high 
dose.  At the highest nicotine yield cigarette, the menthol smokers reported the cigarette 
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to be less satisfying and provided less relief from craving compared to non-menthol 
smokers (Pickworth et al., 2002).  
The second study (Hatsukami et al., 2013) was an initial examination of research 
cigarettes called Spectrum cigarettes (22nd Century Group), which are currently used 
exclusively by the FDA for purposes of examining nicotine content and are the type of 
cigarette used in the present study as well. The nicotine content levels in Spectrum 
cigarettes are altered by genetically modifying the tobacco. Fifty-one participants smoked 
four puffs of three research cigarettes with different nicotine doses (nicotine content 0.4 
mg/g, 5.7-5.8 mg/g, 11.4-12.8 mg/g; nicotine yields >.04 mg, 0.3 mg, 0.6 mg, 
respectively) over the course of a single session in double-blind, random order. 
Participants were assigned menthol or non-mentholated cigarettes based on their usual 
brand preference, with approximately half of participants (47%) being menthol cigarette 
smokers. After smoking each cigarette, participants were given a modified version of the 
CEQ used by Pickworth and colleagues where subjective effects of smoking are rated on 
five subscales (Satisfaction, Psychological Reward, Enjoyment of Respiratory Tract 
Sensations, Aversion, and Craving Reduction). They also assessed Perceived Health Risk 
in which participants rated the perceived disease risk of these products, as well as the  
Multiple Choice Procedure (Griffiths, Troisi, Silverman, & Mumford, 1993), which 
assesses the relative reinforcing effects by having participants indicate at what monetary 
value they would forgo a pack of cigarettes for money. Physiological measures of heart 
rate and blood pressure were collected as well. 
Overall, reducing nicotine content produced ordered, dose-dependent decreases 
across the battery of dependent measures. There were also significant differences in the 
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ratings of the cigarettes between the menthol and non-menthol smokers. Across doses, 
menthol smokers rated the experimental cigarettes as less satisfying, less psychologically 
rewarding, and less pleasing to the respiratory tract compared to non-menthol smokers. 
Menthol smokers also reported smaller craving reductions than non-menthol smokers. A 
similar finding was seen with relative reinforcing effects in the MCP, with menthol 
smokers choosing to switch to money at a lower monetary value indicating less 
reinforcing effects compared to non-menthol smokers. No interaction between menthol 
status and nicotine dose was reported suggesting that ratings were shifted downward 
among menthol compared to non-menthol smokers across the varying dose cigarettes. 
That differs from the results in Pickworth et al. (2002) where differences by menthol 
status were discerned only at high nicotine yield cigarette.  
Considered together, these two studies suggest that when nicotine exposure levels 
are altered, behavioral effects may differ by menthol status, although there is some 
discrepancy over where in the dose-effect curve such discrepancies are discerned. 
Additionally, these two studies leave some gaps where future research is needed. The 
first is the use of a comparison of usual brand relative to research cigarette ratings, which 
neither prior study examined. Having a usual-brand comparison will be useful to see how 
smoking experience of the research cigarettes compares with the participant’s typical 
smoking experience. Finally, findings from the two prior studies could be extended by 
examining effects across additional and more precise outcome measures. For example, 
more precise, well-validated measures of smoking topography, measures of craving and 
withdrawal, and additional measures of relatively reinforcing effects including concurrent 
choice and behavioral-economic tasks could help to elucidate the range and type of 
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outcomes on which menthol and non-menthol users vary in response to reduced nicotine 
cigarettes.  
As discussed above, the overarching goal of FDA-supported research into reduced 
nicotine content cigarettes is to determine how individuals may respond to a policy of 
reduced nicotine standards. The findings from this program of research could have 
substantial impact on current smokers. If menthol and non-menthol smokers respond 
differently to reduced nicotine content cigarettes, it is important to determine as 
thoroughly as possible the nature and breadth of these differences. The aim of the current 
investigation is to use a rigorous, within-subject research design to examine differences 
in behavioral effects by menthol status across a wide range of nicotine content levels 
(0.4mg/g, 2.4mg/g, 5.2mg/g, 15.8mg/g) as well as usual-brand cigarettes across a 
relatively comprehensive battery of outcomes assessing the behavioral pharmacology of 
smoking.  
Methods 
Participants 
 Participants were 26 daily smokers from three subpopulations especially 
vulnerable to smoking being investigated as part of a larger multi-site study involving 
three sites (University of Vermont, John Hopkins University, Brown University). The 
subpopulations are women of reproductive age (n = 9), opioid dependent smokers (n = 
11), and smokers with affective disorders (n = 6). Inclusion criteria that apply across the 
three subpopulations are being 18 years of age or older, smoking greater than or equal to 
five cigarettes per day and providing an expired breath carbon monoxide sample of 
greater than 8ppm to biochemically verify smoking status. Participants also provided a 
negative urine toxicology screen for all illicit substances, except for marijuana (THC) as 
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determined by a multi panel drug test that includes marijuana (THC), cocaine, 
barbiturates, benzodiazepines, buprenorphine, opiates, methadone, oxycodone, 
phencyclidine, and a breath sample at screening with a breath alcohol level (BAL) of < 
.01. Exclusion criteria across the three populations include intention to quit smoking 
within the next month, a past month quit attempt from smoking greater than three days, 
exclusive use of “roll your own” cigarettes, greater than nine days past month use of 
other tobacco products aside from traditional, combustible cigarettes (i.e. smokeless 
tobacco products, cigars, e-cigarettes, and related devices), currently pregnant or trying to 
become pregnant, currently breastfeeding, symptoms of psychosis or dementia as 
determined by the MINI International Neuropsychiatric Interview structured clinical 
interview (MINI; Sheehan et al., 1998), current suicidal ideation, and past suicide attempt 
(past year for those with affective disorders, past ten years for women of reproductive age 
and opioid maintained individuals).  
Specific inclusion criteria for socioeconomically disadvantaged women of 
reproductive age are females between ages 18-44 with less than Associates’ degree and 
not currently enrolled in a degree program. Specific inclusion criteria for opioid 
dependent smokers are currently receiving methadone or buprenorphine for the purposes 
of opioid maintenance, having maintained a stable methadone or buprenorphine dose for 
at least the past thirty days and no more than 30% of past 30 day urine testing positive for 
illicit substances as determined by their maintenance provider or study staff if necessary. 
Specific inclusion criteria for smokers with affective disorder are current or past 12 
months diagnosis of major depressive episode or disorder, dysthymic disorder, 
generalized anxiety disorder, post-traumatic stress disorder, obsessive compulsive 
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disorder, phobia or panic disorder with or without agoraphobia as determined by the 
MINI structured clinical interview. The local Institutional Review Board at each site 
approved the study prior to being conducted and each subject signed written consent.  
Procedure  
 Participants completed fourteen 2-4-hr sessions (> 48-hrs between each session). 
The 14 sessions were organized into three phases: Phase 1 (Sessions 1-5) an assessment 
of smoking topography and subjective effects; Phase 2 (Sessions 6-11) an assessment of 
preference between all dose pairs in a concurrent choice schedule; Phase 3 (Sessions 12-
14) an assessment of preference for each of the three lower doses at a fixed relatively low 
response requirement (Fixed-Ratio 10) vs. the highest dose, which was available on a 
progressive ratio schedule. Due to technical problems, data from Phase 3 is not included 
in the current report. 
All visits were conducted under acute abstinence (< 50% baseline breath CO level 
collected at screening) and participants were instructed to abstain from smoking 6-8-hrs 
prior to the visit to maintain breath CO criterion. Each experimental session was 
scheduled within two hours of the time that the baseline experimental visit was scheduled 
to keep visits at approximately the same time of day within individual participants. Upon 
arrival to the laboratory, participants completed brief physiological measures including 
breath CO, BAL, urine toxicology screen for illicit drugs, weight, heart rate, blood 
pressure, and urine screen for pregnancy, if applicable. Experimental sessions were 
rescheduled for participants who had a breath CO > 50% baseline breath CO level, a 
BAL > .03%, or a positive drug screen for both illicit and licit opioids, aside from 
prescribed methadone or buprenorphine. Positive drug screens for illicit substances 
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excluding opioids resulted in administration of a field sobriety test. If passed, visit was 
continued and if failed, the visit was rescheduled. Those with a positive pregnancy test at 
any point during the study were withdrawn immediately. All visits occurred > 48-hrs 
apart, but within a week of each other. 
 In Phase 1, participants had basic physiological measures taken upon arrival at the 
laboratory followed by two puffs from their usual brand cigarette under staff observation 
to equate time since last cigarette across participants. Experimental sessions began 30-
min following completion of the two puffs. During experimental sessions, participants 
were instructed not to eat, drink any beverages other than water, study, or use their 
cellular phones. Study staff regularly monitored participants during experimental 
sessions. During the 30-min wait period, participants completed two assessments; the 
Minnesota Nicotine Withdrawal Scale (MNWS; Hughes & Hatsukami, 1986) and the 
Questionnaire of Smoking Urges (QSU-Brief; Cox et al., 2001).  
 Participants smoked two cigarettes during each visit. Each cigarette was smoked 
using a CReSS (Clinical Research Support System) Desktop smoking topography device 
(Borgwaldt KC, Richmond, VA). Cigarettes were smoked through a plastic holder that is 
attached to two air filled tubes, which lead to a pressure transducer (see Figure 1). The 
device measures and records a number of smoking topography measures; (1) total 
number of puffs, (2) inter-puff interval (s), (3) puff volume (mL), (4) puff duration (s), 
and (5) maximum puff velocity (mL/s). 
In Session 1 (Baseline session) participants smoked their usual brand cigarette. 
Across the four subsequent experimental sessions in Phase 1 (Sessions 2-5), participants 
smoked one of four research cigarettes (0.4mg/g, 2.4mg/g, 5.2mg/g, 15.8mg/g) ad 
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libitum. Order of smoking the research cigarettes was randomized across sessions and 
participants and was double blind. Research cigarettes were referred to by arbitrary letter 
code and were identical in physical appearance. Participants were instructed to smoke the 
cigarette as they normally would outside of the laboratory.	
Approximately two minutes after extinguishing the first cigarette in Sessions 2-5, 
participants lit a second cigarette of the same dose and smoked it in the controlled 
manner described below. This second cigarette was designed to introduce participants to 
the controlled puffing procedures that were to be used in later phases of the study.  
Participants lit the cigarette without inhaling, inserted the cigarette into the cigarette 
holder filter, then proceeded to begin inhaling until a 60 mL volume of smoke has been 
inhaled which was displayed visually on the computer screen by a counter that increased 
as puff volume increased; a second counter immediately next to the running counter 
showed the goal volume of 60 mL.  Participants were instructed to hold the inhaled puff 
in their lungs for 5 s with a timer counting down the duration displayed on a running 
counter.  Following initiation of a puff, a 30-sec period began to ensure at least that 
amount of time between initiation of each puff with the duration again displayed as a 
running counter on the computer screen. Participants were instructed to not take the next 
puff until all time on the counter had elapsed. Participants followed this regimen until the 
cigarette was smoked down to just above the filter.   
Upon completion of the second cigarette, participants completed the modified 
CEQ (mCEQ; Cappelleri et al., 2007; Westman et al., 1992) and the Cigarette Purchase 
Task (CPT; Jacobs & Bickel, 1999; MacKillop et al., 2008). The mCEQ consists of 12 
questions on five subscales: Smoking Satisfaction, Enjoyment of Respiratory Tract 
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Sensations, Aversion, Craving Reduction, and Psychological Reward. Participants 
answered each question using a Likert scale from zero to seven with an answer of zero 
indicating “not at all” and an answer of seven indicating “extremely”. The CPT uses an 
escalating series of prices to examine the relative reinforcing efficacy of cigarettes by 
assessing estimated cigarette consumption at varying levels of economic constraint in a 
24-hr period when there is no access to any other nicotine products. In the current study, 
the CPT assesses consumption of cigarettes using a 17 point scale evaluating how much 
one would smoke when the cost is $0.00/cigarette increasing until cost of the cigarette is 
$5.00/cigarette. The CPT generates an individual demand curve using five indices: (a) 
Intensity (cigarette smoking when unconstrained by cost), (b) Omax (maximum amount of 
money one is willing to spend on smoking per day), (c) Pmax (price at which demand 
decreases proportional to price increasing price) (d) Breakpoint (price at which one 
would quit smoking rather than incur the cost), and, (e) Elasticity of Demand (overall 
sensitivity of smoking rate to price). Additionally, breath CO to measure CO boost, as 
well as withdrawal and craving as measured by the MNWS and QSU-brief were 
measured every 15 minutes in the hour following completion of smoking the second 
cigarette. To measure CO boost, pre-cigarette CO was subtracted from CO from each 
value measured at each of the four time points after smoking the cigarette. 
 Phase 2 consisted of six 4-hr sessions. Upon arrival at the laboratory, participants 
followed procedures identical to Phase 1 sessions. Experimental sessions began 30 
minutes following completion of the two cigarette puffs that equate time since last 
smoking across participants. During the 30-min wait period, participants again completed 
the MNWS and the QSU-brief. After 30-min elapsed, participants completed a 3-hr 
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concurrent choice task. Upon initiation of the task participants were presented with two 
different packs of cigarettes, each with a different letter code. Across the six sessions, 
participants experienced all available dose pairs (15.8mg/g v. 0.4 mg/g, 15.8mg/g v. 2.4 
mg/g, 15.8mg/g v. 5.2 mg/g, 5.2 mg/g v. 2.4 mg/g, 5.2 mg/g v. 0.4 mg/g, 2.4 mg/g v. 0.4 
mg/g) under double-blind conditions with each dose identified by letter code. Order of 
dose pairings was randomized across participants and letter codes corresponded to the 
letter codes in Phase 1. Participants were instructed to attend to the notes they had made 
about each research cigarette to inform their choices during the concurrent task. In the 
chamber participants faced a computer screen displaying two 1.25-inch squares. Each 
square contained a letter code indicating the two research cigarettes available that 
session. Participants were instructed to smoke as much or as little as they want. 
Participants indicated a desire to smoke by using a computer mouse to complete 10 clicks 
on the letter code of the cigarette they wished to smoke. After completion of the 10 
clicks, a 3-min counter appeared on the screen during which the participant could take 
two puffs from the selected cigarette in the controlled manner that they had practiced in 
Phase 1. Once two puffs were completed, the cigarette was extinguished and the butt 
placed in a disposal container. Each smoking choice during a session involved 
participants lighting a new cigarette. This controlled puffing procedure is used to control 
for any between or within subject differences in smoking topography and to assure that 
all puffs are taken from the same part of the cigarette. At completion of the 3-hr session, 
participants again complete the MNWS and the QSU-brief. 
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Study Product 
 Study product was Spectrum investigational research cigarettes manufactured by 
22nd Century Group (Clarence, NY). Four nicotine dose conditions were investigated 
using research cigarettes defined by a nicotine content that was an average across 
menthol and non-menthol products (assignment of a menthol or non-menthol product was 
based on a participant’s reported usual brand and self-reported preference of menthol or 
non-menthol product during the duration of the study): 15.8, 5.2, 2.4, and 0.4 mg/g. For 
the 15.8 mg/g dose, the average nicotine content for the menthol product was 15.46 mg/g 
and the average nicotine content for non-menthol product was 16.21 mg/g. For the 5.2 
mg/g dose, the average nicotine content for the menthol product was 5.22 mg/g and the 
nicotine content for average non-menthol product was 5.12 mg/g. For the 2.4 mg/g dose, 
the nicotine content for the average menthol product was 2.38 mg/g and the nicotine 
content for average non-menthol product was 2.32 mg/g. Finally for the 0.4 mg/g dose, 
the average nicotine content for the menthol product was 0.39 mg/g and the average 
nicotine content for non-menthol product was 0.38 mg/g. Hereafter, doses will be 
referred to by the nicotine content averaged across menthol and non-menthol product: 
15.8, 5.2, 2.4, and 0.4 mg/g. The highest dose (15.8 mg/g) is relatively similar to nicotine 
content in current commercial cigarettes and the lowest dose (0.4mg/g) is below the 
proposed threshold of nicotine dependence (Benowitz & Henningfield, 1994). As 
reported by the Center for Disease and Control, average menthol content of the 
mentholated research cigarettes ranges from 4.97 mg/cigarette to 7.72 mg/cigarette, with 
an average menthol content of 5.98 mg/cigarette at the 0.4mg/g dose, 4.97 mg/cigarette at 
the 2.4 mg/g dose, 6.15 mg/cigarette at the 5.2 mg/g dose, and 7.13 mg/cigarette at the 
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15.8 dose (Richter et al., 2016). These menthol contents are similar to commercial 
mentholated cigarettes (Ai et al., 2016). These cigarettes also differed in the content or 
yield of minor alkaloids and nitrosamines and in the application of casings, including 
sugars (which were higher in the cigarettes with 15.8 mg/g than in the reduced-nicotine 
cigarettes in order to balance the ratio of nicotine to sugar) (Donny et al., 2015).   
Statistical Methods 
 Analysis of differences between menthol and non-menthol in demographic 
variables and smoking characteristics were conducted using independent samples t-tests 
for continuous variables and Pearson’s chi-square test for categorical variables. For any 
categorical variables with categories involving less than five subjects, Fischer’s Exact 
Tests were conducted.  
 Differences in mCEQ, CPT, and smoking topography were determined using 
repeated analysis measures of variance, with menthol status (use of non-menthol versus 
menthol cigarettes) as the between-subjects factor and nicotine dose (0.4, 2.4, 5.2, 15.8 
mg/g, Usual Brand) as the within-subject factor. Analyses of MNWS, QSU, and CO 
boost used a similar approach, however, time (pre- and post-cigarette within each 
session) was added as an additional within-subject factor and nicotine dose will only 
include research cigarette doses (0.4, 2.4, 5.2, 15.8 mg/g) and not Usual Brand. 
Significant menthol, time, and dose effects and interactions were followed by post-hoc 
tests to fully explain the nature of the differences. The CPT consist of five indices; 
Intensity, Breakpoint, Pmax, Omax, and Elasticity. Breakpoint, Pmax, Omax, and 
Elasticity were log transformed and the indice Intensity was square root transformed to 
meet normality assumptions. Differences between pairings in all the six dose pairings in 
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the concurrent choice task were also similarly examined using repeated measures analysis 
of variance with menthol status as the between-subjects factor and nicotine dose pair as 
the within-subjects factors. Post-hoc testing followed to determine which specific dose 
pairs evoke the greatest differences by menthol status with the higher dose chosen at a 
statistically significantly higher proportion than chance. Additionally, we examined any 
differences in smoking bouts (i.e. number of puffs taken during Phase 2 choice 
procedures) by menthol and non-menthol groups. Significance for all tests was set at p < 
.05 (two tailed).   
Primary Outcomes 
We examined differences by menthol status and interactions of menthol status and 
nicotine dose in the dependent measures discussed above. More specifically, differences 
in the mCEQ, the CPT, the MNWS, QSU-brief, smoking topography indices, and CO 
boost were examined from Phase 1. From Phase 2, differences in proportion of choices 
allocated to the higher dose across the 6-possible dose pairs were examined, as well as 
overall number of smoking bouts per session. 
Results 
Participant Characteristics 
Among the 26 participants, 42% (n = 11) used menthol cigarettes as their usual 
brand and 58% (n = 15) used non-menthol cigarettes. Menthol and non-menthol smokers 
were mainly female smokers in their mid thirties with the majority having a high school 
education or less. Menthol smokers were significantly more likely to be non-white than 
non-menthol smokers (Table 1).  
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mCEQ 
As hypothesized, ratings of menthol cigarettes fell below those of the non-
menthol cigarettes in four of the five mCEQ subscales (Figure 1) with menthol smokers 
rating the cigarettes lower than non-menthol smokers. On the Psychological Reward 
subscale, there was a main effect of menthol status (F(1,24) = 4.74, p < .05) and an 
interaction of menthol and nicotine dose (F(4,96) = 2.90, p < .05) with menthol ratings 
overlapping with non-menthol in the usual brand cigarette comparison, but falling below 
non-menthol ratings across each of the research cigarette doses. In contrast to the pattern 
seen with menthol cigarettes, ratings of the non-menthol cigarettes did not change from 
usual-brand levels across the differing research cigarette doses. Similar interactions of 
menthol status nicotine dose were seen with the subscales Smoking Satisfaction (F(4,96) 
= 2.83, p < .05) and Enjoyment of Respiratory Tract Sensations (F(4,96) = 2.78, p < .05). 
Post-hoc testing across the three subscales with menthol by nicotine dose interactions, 
showed significantly lower ratings of the research cigarettes compered to usual brand 
among menthol (ps < .05) but not non-menthol smokers. Menthol status produced a main 
effect on the Craving Reduction subscale with menthol status ratings falling below non-
menthol ratings across all dose comparisons (F(1,24) = 14.24, p < .001). No main effect 
of menthol or interaction of menthol status and nicotine dose were observed on the 
Aversion subscale. As expected, nicotine dose produced a main effect across all five 
mCEQ subscales of the (Fs(4,96) > 2.79, ps < .01).  
CPT  
There were no main effects of menthol status on the five CPT indices, but there 
were three significant interactions of menthol status and nicotine dose on Breakpoint, 
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Elasticity, and Omax (Figure 2, Panels A, B, and C respectively), and two trending in the 
same direction, Pmax and Intensity (Panels D and E respectively). Regarding the three 
indices with significant interactions, ratings of the usual brand menthol cigarette either 
overlapped with or indicated greater value than the non-menthol cigarette. Thereafter, 
changes in the direction of lower value or reinforcing efficacy relative to usual brand was 
seen across the menthol research cigarettes whereas scores of the non-menthol research 
cigarettes changed little relative to usual brand (Fs(4,88) = 3.52, ps < .05). Post-hoc 
testing revealed menthol smokers reported lower values for the research cigarettes 
compared to usual brand (ps < .05) while non-menthol cigarette smokers did not. Similar 
patterns were seen with the two indices with non-significant trends towards an interaction 
(Fs(4,88) < 2.24, ps = .07). There was a significant main effect of nicotine dose across 
four of the five CPT indices (Breakpoint, Elasticity, Omax, and Pmax) (Fs(4,88) > 3.54, 
ps < .01).  
Direct Testing of Reductions in Addiction Potential 
Direct tests of preference across dose pairs in the concurrent-choice arrangement 
were of interest for assessing differences in the relative reinforcing effects of the research 
cigarettes by menthol status. There was no main effect of menthol status nor a menthol 
dose interaction. There was a significant main effect of nicotine dose (F(5,110) = 2.37, p 
< .05), with participants preferring the higher of the doses. Post hoc testing revealed that 
those differences were attributable to three dose pairs (0.4 v 15.8, 2.4 v 15.8, 2.4 v 5.2) 
(Figure 3, Panel A). Exploratory analyses of those same dose pairs by menthol status 
indicated that the preference for the higher over the lower dose was significant (p < .05) 
among the non-menthol, but not the menthol smokers (Figure 3, Panel B).  
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An analysis of the average number of total puffs across dose pairs was examined 
by menthol status to determine any differences in overall smoking levels. Mean number 
of choices to smoke in the menthol group were somewhat lower than choices of non-
menthol (9.50 + 6.76 versus 16.37 + 13.37) but that difference was not significant (p = 
.11). 
MNWS and QSU-brief Ratings 
Nicotine withdrawal and craving were of interest to determine if there were 
differences by menthol status in the amount of relief produced by smoking. Craving and 
withdrawal ratings were not collected for usual-brand cigarettes, thus analyses are 
restricted to the four research cigarettes. 
Regarding the MNWS total score and desire to smoke item, there was no main 
effect of menthol status, however there was a main effect of time on both MNWS Total 
score  (F(4, 96) = 11.39, p < .001), and MNWS desire to smoke item (F(4,94) =29.41, p < 
.01) suggesting ratings of withdrawal and craving immediately decreased relative to 
baseline (pre-smoking) and increased as time elapsed post-smoking (Figure 4). There was 
a significant interaction of menthol status and time with reductions in withdrawal relative 
to baseline (pre-smoking) ratings being discernible among the non-menthol smokers but 
not the menthol smokers (MNWS Total score: (F(4,96) = 5.39, p  < .001; MNWS desire 
to smoke item: (Fs(4,96) = 5.36, p < .05). There was no main effect of nicotine dose on 
the MNWS, nor interactions of dose with menthol or time.  
There was no main effect of menthol status on Factors 1 or 2 of the QSU-brief.  
There was a main effect of time on Factors 1 (F(4,95) = 33.08, p < .001) and 2 (F(4,96) = 
28.26, p < .001), but no significant interactions of menthol status and time. There were no 
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main effects of nicotine dose nor significant interactions of dose, time, and menthol status 
on either QSU factor. There was a nonsignificant trend towards an interaction of menthol, 
time, and dose for both Factors 1 (F(12,287) = 1.77, p = .05) and 2 (F(12,287) = 1.74, p = 
.06) corresponding to the highest research dose cigarette producing larger reductions in 
craving at the 15- and 30-minute assessments among non menthol compared to menthol 
smokers (data not shown).   
Smoking Topography and CO Boost 
Smoking topography and CO boost were of interest due to potential concerns of 
low nicotine content cigarettes increasing compensatory smoking (i.e. larger puff volume, 
longer puff duration) and the possibility of differences in this behavior by menthol status. 
Smoking topography was examined across usual brand cigarettes and the research 
cigarettes, while CO boost was restricted to only the research cigarettes.  
Across the five indices of smoking topography, there were no main effects of 
menthol or menthol by nicotine dose interactions, however there was a non-significant 
trend towards a main effect of menthol status for Mean Puff Volume (F(1,16) = 4.32, p = 
.05) corresponding to a lower puff volume among menthol smokers relative to non-
menthol smokers. There was a main effect of nicotine dose on Inter-puff Interval (F(4,60) 
= 2.57, p < .05), but no other main effects of nicotine dose across the remaining indices 
(Mean Puff Volume, Puff Duration, Number of Puff, Maximum Flow Rate) (data not 
shown). 
In regards to CO boost following acute exposure, there was no significant effect 
of menthol status, dose, or menthol by dose interactions. There was a significant main 
effect of time (F(3,288) = 8.92, p < .001) with CO levels decreasing across time (data not 
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shown). Overall, these results show no evidence of compensatory smoking by menthol 
status or dose.  
Effect of Race on Menthol  
It is important to note that although menthol and non-menthol smokers differed 
significantly by race, we were unable to control for race in the analyses due to the 
homogenous non-menthol sample (i.e. all identifying as Caucasian). To explore the 
possibility that differences in the mCEQ, CPT, and concurrent choice testing (Phase 2 
dose comparisons) may have been an artifact of including racial minorities in the menthol 
but not the non-menthol conditions, we plotted results restricting the data to on  
participants who identified as Caucasian (Figure 5). Patterns seen in the complete data 
persisted in the sample restrict to Caucasian only, suggesting that the menthol status 
differences were not attributable to racial differences between the menthol and non-
menthol conditions. 
Conclusions 
Overall, the results from this within-subjects study of acute exposure to varying 
nicotine content cigarette suggests that menthol smokers respond differently than non-
menthol smokers and those differences follow two distinct patterns. The first pattern is a 
reduced acceptability of the research cigarettes in menthol compared to non-menthol 
smokers. This lowered response to the research cigarettes across doses among the 
menthol relative to non-menthol smokers is seen across measures of positive subjective 
effects, withdrawal and craving ratings, and reinforcing efficacy. The findings from both 
the subjective ratings and reinforcing efficacy are consistent with the results reported by 
Hatsukami et al. (2013) where menthol smokers showed less pleasurable subjective and 
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reinforcing effects of research cigarettes compared to non-menthol smokers across 
multiple doses of Spectrum research cigarettes. The present results also extended those 
results by demonstrating that menthol smokers also report reduced relief from nicotine 
withdrawal and desire to smoke compared to non-menthol smokers. 
A second pattern seen in the present results is that menthol smokers compared to 
non-menthol rate the research cigarettes considerably less satisfying and reinforcing than 
their usual brand cigarette whereas non-menthol smokers did that to a lesser extent. This 
difference between menthol and non-menthol smokers was observed on the CPT and the 
mCEQ measures. To our knowledge, comparisons of usual brand and research cigarettes 
by menthol status have not been reported previously.  
There are several possible explanations for why these differences by menthol 
status may occur. One possibility is that they are attributable to participant self-selection 
into the menthol and non-menthol categories. While we cannot rule out that possibility 
regarding participant characteristics not assessed in this study, among those 
characteristics that were compared between menthol and non-menthol smokers, only race 
differed significantly. We could not control for race statistically but when results were 
examined among only Caucasians, similar patterns of menthol versus non-menthol 
differences remained discernible (See Results and Figure 5), rendering confounding by 
race as an inadequate account of the results.  
Another potential explanation is that the menthol content differs between 
commercially marketed cigarettes and the Spectrum research cigarettes.  However, the 
most recent analyses of commercially marketed and Spectrum cigarettes (Ai et al., 2016 – 
currently marketed cigarettes; Richter et al., 2016 – Spectrum cigarettes) suggest that 
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Spectrum research cigarettes fall well within the middle of the range of menthol content 
levels (See Ai et al., 2016 for most up to date analyses). In the current study, average 
menthol content of usual brand cigarettes among menthol smokers was 4.99 (+ .194) 
mg/cigarette and the Spectrum cigarettes used in the current study had an average 
menthol content of 6.25 (+ .472) mg/cigarette. Although menthol content of usual brand 
was slightly lower than Spectrum cigarettes, both of these values are well within range of 
“normal” menthol content reported by Ai et al (2016). None of the menthol smokers in 
our sample for whom we had data had menthol contents that were outliers (Range: 3.84 – 
5.30), although menthol content of usual brand in the current study was only available for 
8/11 (73%) of the menthol smokers. 
A final possible explanation for the findings could be greater unwillingness to 
switch products among menthol compared to non-menthol smokers. Although data 
examining this is sparse, Strasser et al. (2013) showed decreases in satisfaction among 
menthol smokers when they were switched from their usual brand to a different 
commercial mentholated product (Camel Crush). These results in combination with 
findings from the current study suggest that this lowered rating of the research cigarette 
relative to usual brand may not be specific to Spectrum cigarettes, but may be a 
characteristic of menthol smokers. More research comparing brand switching between 
menthol and non-menthol smokers is needed to support this conclusion. 
The present study has several limitations that merit mention. One that was 
discussed above is the inability to control for racial differences in the sample, although 
excluding minorities from the analyses did not appear to alter the pattern of results to any 
meaningful extent. Another limitation is the relatively small sample size and one that was 
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restricted to populations who are especially vulnerable to smoking. However, the results 
were sufficiently robust to discern statistically significant results across multiple 
dependent measures and the results were consistent with prior studies using other 
populations. These limitations notwithstanding, the present findings suggest that 
mentholated Spectrum research cigarettes produce less pleasurable subjective effects, less 
relief from withdrawal and craving, and lower reinforcing efficacy among smokers whose 
usual brand is mentholated compared to non-mentholated. Further research will be 
necessary to determine why this difference is occurring, but researchers involved in 
tobacco regulatory science should be aware of this replicable observation and should 
consider its implications when conducting research with menthol smokers. Does this 
difference occur because Spectrum cigarettes are overall less palatable to menthol 
smokers due to some limitation of the research cigarette or is it because menthol smokers 
are less likely to be amenable to switching brands more generally? These are important 
questions to resolve that have potentially important implications for tobacco regulatory 
research.  
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Table 1. Demographics  
 
  Menthol         (n =11) 
Non-Menthol 
(n = 15) p value 
Age (M + SD) 35.73 + 12.06 37.4 + 10.12 .7 
Gender (% Female) 72.7% 80% .67 
Race (% White) 55% 100% .03 
Education (%)   1.0 
       Some High School 27.3% 20%  
       High School   
Grad./Equivalent 45.5% 40% 
 
       Some College/2-Yr 
Degree 27.3% 33.3% 
 
       College Graduate/4-Yr 
Degree 0% 6.7% 
 
Marital Status (%)   .13 
     Never Married 90.9% 46.7%  
     Remarried 0% 13.3%  
     Separated 0% 20.0%  
     Divorced 9.1% 6.7%  
     Widowed 0% 13.3%  
Cigarettes per Day (M + 
SD) 16.46 + 7.78 18.27 + 11.8 .66 
Nicotine Yield (M + SD) 1.25 + 0.21 1.19 + 0.27 .59 
Cigarette Type (%)   .4 
       Full Flavor 90.9% 78.6%  
       Light 9.1% 21.4%  
Age Started Smoking 
Regularly (M + SD) 15 + 2.05 15.47 + 2.13 .58 
Fagerström Test for 
Nicotine Dependence (M + 
SD) 
4.63 + 2.24 5.53 + 2.97 .41 
Note.  Values in the table are reported as means + standard deviations unless otherwise 
noted. Nicotine yield values come from the Federal Trade Commission’s Tar, Nicotine, 
and Carbon Monoxide Report from 1999-2005. Data on cigarette type and yield was not 
available for 1 participant. 
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Figure Legends 
 
Figure 1. Panels A-E: Mean + SEM for Modified Cigarette Evaluation Scale for menthol 
and non-menthol across usual brand (UB) and the four research cigarettes (0.4mg/g, 
2.4mg/g, 5.2mg/g, 15.8mg/g). A main effect of nicotine dose was seen across subscales, a 
main effect of menthol status was seen at the Craving Reduction subscale (Panel D), and 
an nicotine dose menthol interaction effect was seen at Smoking Satisfaction(Panel A), 
Psychological Reward (Panel B), and Enjoyment of Respiratory Tract Sensations (Panel 
C). An asterisk (*) indicates a significant effect of group at doses in subscales with an 
interaction.  
 
Figure 2. Panels A-E: Mean + SEM for the Cigarette Purchase Task for menthol and 
non-menthol across usual brand (UB) and the four research cigarettes (0.4mg/g, 2.4mg/g, 
5.2mg/g, 15.8mg/g). Panel A: Breakpoint (estimated price at which participants would 
quit smoking rather than incur its costs).Panel B: Elasticity(estimated overall sensitivity 
of demand to price increases). Panel C: Omax (estimated maximal expenditure 
participants were willing to incur for smoking in one day). Panel D: Pmax (estimated 
price where demand begins to decrease proportional to price increases).  Panel E: 
Intensity (estimated consumption levels across prices ranging from $0 to $40/cigarette). 
A main effect of nicotine dose was seen for four of the five indices; Breakpoint (Panel 
A), Elasticity (Panel B), Pmax (Panel C), Omax (Panel D) and a nicotine dose menthol 
interaction was seen at Breakpoint, Omax, Pmax. Breakpoint (Panel A), Elasticity (Panel 
B), Omax (Panel C), and Pmax (Panel D) are all log transformed and Intensity (Panel E) 
is square root transformed. No significant effect of group was seen at doses in indices 
with an interaction effect. 	
 
Figure 3. Mean proportion of choices for three nicotine dose pairs across concurrent 
choice sessions. Data points are mean across participants by menthol status and error bars 
represent + SEM. The varying two-dose comparisons are shown on the x-axis with mean 
proportion of choice allocated to each shown on the y-axis. Panel A: Proportion of 
choices across dose pairs across all subjects. Panel B: Proportion of choices across dose 
pairs by menthol and non-menthol smokers. Asterisks (*) indicate that the higher dose 
was chosen at significantly greater than chance level. 
	
Figure 4.  Mean + SEM for the Minnesota Nicotine Withdrawal Scale Total Score and 
restricted to one item; Desire for menthol and non-menthol pre smoking and across time 
points post smoking (15, 30, 45, 60 minutes) and across four research cigarettes 
(0.4mg/g, 2.4mg/g, 5.2mg/g, 15.8mg/g). Data points are mean across participants by 
menthol status and error bars represent + SEM. Panel A: MNWS Total Score across 
menthol subjects. Panel B: MNWS Total Score across non-menthol subjects. Panel C: 
MNWS Desire Item across menthol subjects. Panel D: MNWS Desire Item across non-
menthol subjects.  
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Figure 5. Comparison of menthol data including all subjects and restricted to include 
only white smokers. Panel A: Mean + SEM for the subscale Smoking Satisfaction on the 
Modified Cigarette Evaluation Scale for menthol and non-menthol across usual brand 
(UB) and the four research cigarettes (0.4mg/g, 2.4mg/g, 5.2mg/g, 15.8mg/g) including 
all menthol subjects. 
Panel B: Mean + SEM for the subscale Smoking Satisfaction on the Modified Cigarette 
Evaluation Scale for menthol and non-menthol across usual brand and the four research 
cigarettes (0.4mg/g, 2.4mg/g, 5.2mg/g, 15.8mg/g) including only white menthol subjects. 
Panel C: Mean + SEM for the Cigarette Purchase Task indice Breakpoint for menthol and 
non-menthol across usual brand and the four research cigarettes (0.4mg/g, 2.4mg/g, 
5.2mg/g, 15.8mg/g) including all menthol subjects. 
Panel D: Mean + SEM for the Cigarette Purchase Task indice Breakpoint for menthol and 
non-menthol across usual brand and the four research cigarettes (0.4mg/g, 2.4mg/g, 
5.2mg/g, 15.8mg/g) including only white menthol subjects. 
Panel E: Mean proportion of choices by menthol status allocated to the different nicotine 
dose cigarettes across three 3-hour two-dose concurrent choice sessions included all 
menthol subjects. Data points are mean across participants by menthol status and error 
bars represent + SEM. 
Panel F: Mean proportion of choices by menthol status allocated to the different nicotine 
dose cigarettes across three 3-hour two-dose concurrent choice sessions included only 
white menthol subjects. Data points are mean across participants by menthol status and 
error bars represent + SEM. 
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Figure 1. mCEQ Subscales by Menthol Status Across Dose
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Figure 2. CPT Indices by Menthol Status Across Dose 
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Figure 3. Concurrent Choice Test Across Dose Pairs 
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Figure 4. MNWS by Menthol Status Across Dose  
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Figure 5. Comparison of Limited Sample for Examination of Effect of Race 
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